ABACAVIR , LAMIVUDINE AND ZIDOVUDINE

FDA Drug Profile — ABACAVIR, LAMIVUDINE AND ZIDOVUDINE

Drug Details

Generic Name
ABACAVIR , LAMIVUDINE AND ZIDOVUDINE
Brand Names
ABACAVIR, LAMIVUDINE AND ZIDOVUDINE
Application Number
ANDA202912
Sponsor
Lupin Pharmaceuticals, Inc.
NDC Codes
1
Dosage Forms
TABLET
Routes
ORAL
Active Ingredients
ABACAVIR SULFATE, LAMIVUDINE, ZIDOVUDINE

Indications and Usage

1 INDICATIONS AND USAGE Abacavir, lamivudine and zidovudine tablet, a combination of abacavir, lamivudine, and zidovudine, each nucleoside analogue HIV-1 reverse transcriptase inhibitors, is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.( 1 ) Abacavir, lamivudine and zidovudine tablet is indicated in combination with other antiretrovirals or alone for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. Limitations of Use: Limited data exist on the use of abacavir, lamivudine and zidovudine tablets alone in patients with higher baseline viral load levels (greater than 100,000 copies per mL) [see CLINICAL STUDIES ( 14 )] .